2.05
price up icon5.67%   0.11
after-market 시간 외 거래: 2.02 -0.03 -1.46%
loading
전일 마감가:
$1.94
열려 있는:
$1.93
하루 거래량:
4.69M
Relative Volume:
1.08
시가총액:
$860.87M
수익:
-
순이익/손실:
$-75.80M
주가수익비율:
-5.8571
EPS:
-0.35
순현금흐름:
$-68.07M
1주 성능:
+9.04%
1개월 성능:
-12.39%
6개월 성능:
-20.85%
1년 성능:
-31.21%
1일 변동 폭
Value
$1.90
$2.07
1주일 범위
Value
$1.81
$2.10
52주 변동 폭
Value
$1.54
$3.97

Nuvation Bio Inc Stock (NUVB) Company Profile

Name
명칭
Nuvation Bio Inc
Name
전화
(415) 754-3517
Name
주소
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Name
직원
273
Name
트위터
Name
다음 수익 날짜
2025-03-05
Name
최신 SEC 제출 서류
Name
NUVB's Discussions on Twitter

NUVB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NUVB
Nuvation Bio Inc
2.05 860.87M 0 -75.80M -68.07M -0.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-23 개시 Citizens JMP Mkt Outperform
2024-03-27 업그레이드 Jefferies Hold → Buy
2024-03-26 업그레이드 BTIG Research Neutral → Buy
2023-01-06 다운그레이드 Jefferies Buy → Hold
2022-08-02 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-08-02 다운그레이드 BTIG Research Buy → Neutral
2022-05-04 개시 H.C. Wainwright Buy
2021-10-15 재개 BTIG Research Buy
2021-04-06 개시 RBC Capital Mkts Outperform
2021-03-08 개시 BMO Capital Markets Outperform
2021-03-08 개시 BTIG Research Buy
2021-03-08 개시 Cowen Outperform
2021-03-08 개시 Jefferies Buy
2021-03-08 개시 Wedbush Outperform
모두보기

Nuvation Bio Inc 주식(NUVB)의 최신 뉴스

pulisher
Jun 18, 2025

Insider Buying: Stacy Markel Acquires 10,000 Shares of Nuvation Bio Inc (NUVB) - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nuvation Bio (NUVB): RBC Capital Maintains Rating, Lowers Price Target | NUVB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nuvation Bio (NUVB) Target Price Revised Amid Commercial Shift | NUVB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RBC Cuts Price Target on Nuvation Bio to $6 From $10, Keeps Outperform, Speculative Risk - MarketScreener

Jun 17, 2025
pulisher
Jun 16, 2025

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc. - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Onco360 Has Been Selected as a National Specialty Pharmacy - GlobeNewswire

Jun 16, 2025
pulisher
Jun 13, 2025

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

Buy Rating for Nuvation Bio’s IBTROZI: FDA Approval and Competitive Edge in ROS1+ NSCLC Treatment - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 12, 2025

FDA Approves Nuvation Bio’s Ibtrozi for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer - PharmExec

Jun 12, 2025
pulisher
Jun 12, 2025

'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals

Jun 12, 2025
pulisher
Jun 12, 2025

U.S. FDA Approves Nuvation Bio’s Ibtrozi - Contract Pharma

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Scores First FDA Nod With Oral Lung Cancer Drug - BioSpace

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtro - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer - PMLiVE

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio stock falls after FDA approves lung cancer drug By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

FDA approves Nuvation Bio’s Ibtrozi for ROS1-positive NSCLC - The Pharma Letter

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio stock falls after FDA approves lung cancer drug - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

Nuvation Bio (NUVB) Gains FDA Approval for Lung Cancer Drug Ibtr - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Trading Halted Amidst Anticipated Announceme - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche - BioPharma Dive

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio’s IBTROZI Receives FDA Approval - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Set For First Launch With Ibtrozi In Lung Cancer - insights.citeline.com

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer Drug IBTROZI | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wed - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Stock Rating Maintained at Outperform by Wedbush | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

# FDA approves Nuvation Bio’s lung cancer drug taletrectinib By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

US FDA approves Nuvation Bio’s lung cancer therapy - WSAU

Jun 11, 2025
pulisher
Jun 11, 2025

US FDA approves Nuvation Bio's rare lung cancer drug - Reuters

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZ - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Shares Decline Despite FDA Approval of Ibtrozi | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

# FDA approves Nuvation Bio’s lung cancer drug taletrectinib - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Trading Resumes | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gets Boost as FDA Approves Ibtrozi for Lung Cancer | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio scores first FDA approval for new lung cancer drug - Endpoints News

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Gains FDA Approval for Advanced Lung Cancer - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation kinase inhibitor wins FDA approval in non-small cell lung cancer - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio stock in focus as FDA clears Ibtrozi (NUVB:NYSE) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio announces FDA approval of Ibtrozi for advanced ROS-1+ NSCLC - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Grants Approval to Nuvation Bio's Ibtrozi for Lung Cancer Treatment (NUVB) | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer – Company AnnouncementFT.com - Financial Times

Jun 11, 2025
pulisher
Jun 11, 2025

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Mid Florida Newspapers

Jun 11, 2025
pulisher
Jun 11, 2025

Nuvation Bio (NUVB) Shares Surge Following FDA Approval | NUVB Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

US FDA approves Nuvation Bio's lung cancer therapy - TradingView

Jun 11, 2025

Nuvation Bio Inc (NUVB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Nuvation Bio Inc 주식 (NUVB) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Sauvage Philippe
Chief Financial Officer
Jun 17 '25
Buy
1.79
4,000
7,160
9,902
Sauvage Philippe
Chief Financial Officer
Jun 16 '25
Buy
1.83
3,300
6,056
5,902
Sjogren Colleen
Chief Commercial Officer
Jun 16 '25
Buy
1.81
50,000
90,350
81,000
Wentworth Kerry
CHIEF REGULATORY OFFICER
Jun 16 '25
Buy
1.79
50,000
89,740
50,000
Hung David
PRESIDENT AND CEO
Jun 16 '25
Buy
1.79
500,000
893,500
59,281,054
Liu Dongfang
CHIEF MEDICAL OFFICER
May 02 '25
Option Exercise
1.94
20,000
38,800
32,000
Liu Dongfang
CHIEF MEDICAL OFFICER
May 02 '25
Sale
2.50
20,000
50,024
12,000
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):